Market cap
$884m
Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.
Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.
Viatris also holds exclusive development and commercialization rights to nebulized revefenacin in China and adjacent territories, which include the Hong Kong SAR, the Macau SAR, and Taiwan (collectively, the “China Region”), and the Company is eligible to receive tiered royalties ranging from 14 % to 20 % on net sales of nebulized revefenacin in the China Region. As of June 30, 2026, the Company is eligible to receive from Viatris potential global sales and regulatory milestone payments (excluding the China Region) up to $ 180.0 million in the aggregate, with $ 135.0 million associated with YUPELRI monotherapy and $ 45.0 million associated with future potential combination products. …Theravance Biopharma, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-11